Recruiting

Observational Study

Sponsor:

xCures

Code:

NCT06539169

Conditions

Alpha-Thalassemia

Beta-Thalassemia

Amyloidosis

Amyotrophic Lateral Sclerosis

Creutzfeld-Jakob Disease

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in the study by electronic consent (eConsent) and sign a medical records release to permit data collection. Medical records are accessed from institutions directly via eFax or paper fax, online from patient electronic medical record (EMR) portals, direct from DNA/RNA sequencing and molecular profiling vendors, and via electronic health information exchanges. Patients and their treating physicians may also optionally provide medical records. Medical records are received in or converted to electronic/digitized formats (CCDA, FHIR, PDF), sorted by medical record type (clinic visit, in-patient hospital, out-patient clinic, infusion and out-patient pharmacies, etc.) and made machine-readable to support data annotation, full text searches, and natural language processing (NLP) algorithms to further facilitate feature identification.

Conditions

Alpha-Thalassemia

Beta-Thalassemia

Amyloidosis

Amyotrophic Lateral Sclerosis

Creutzfeld-Jakob Disease

Study ID

NCT06539169

Start date

Jun 10, 2024

Status verified date

Aug, 2024

Completion date

Jun 10, 2026

Anticipated

Primary completion date

Jun 10, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Any person with a known or suspected rare disease, defined by their prevalence of fewer than 200,000 individuals nationwide. Diseases include but are not limited to:

Alpha- or Beta- Thalassemia Amyloidosis Amyotrophic Lateral Sclerosis (ALS) Creutzfeldt-Jakob disease (CJD) Cystic Fibrosis (CF) Duchenne Muscular Dystrophy (DMD) Early-onset Alzheimer's Disease Ehlers-Danlos Syndrome (EDS) Huntington's Disease (HD) Gaucher Disease GM1 Gangliosidosis Myasthenia Gravis Pompe Disease Sickle Cell Disease Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Transthyretin Amyloid Polyneuropathy (ATTR-PN)

- Patients or their legally-authorized representative must be willing and able to provide informed consent (and assent, if applicable). Deceased persons may participate via consent of their legally-authorized representative in accordance with applicable Federal and state laws

Exclusion Criteria:

  • Patient or LAR is unable to provide informed consent.
  • Patient resides in a country other than the United States and is unable to provide access to medical records.

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Overall Survival (OS) [ Time Frame: 5 Years ]
  • Safety/tolerability of medications [ Time Frame: 5 years ]
  • Changes in normal development milestones [ Time Frame: 5 years ]
  • Changes in functional status [ Time Frame: 5 years ]
  • Changes in motor function [ Time Frame: 5 years ]
  • Changes in symptoms or clinical status [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Locations

xCures

Recruiting

Los Altos, California, United States, 94022

Contacts

More Information

Sponsor

xCures

Last update posted

Nov 14, 2024

Last verified

Aug, 2024

Keywords

  • rare diseases

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-24. This information was provided to ClinicalTrials.gov by xCures on 2024-11-14. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.